Nasdaq · CIK 0001953926
ZBIO Zenas BioPharma, Inc.
Insider trading from SEC Form 4. Last filing 40 d ago. Close $27.26 on Oct 9, 2026, +79% from the 52-week low and -37% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
15
with a Form 4 at this company
Price and insider trades, last year
ZBIOOct 9, 2026 · close 27.26
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Zenas BioPharma, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 49Moderate | Patricia L Allen director buy | $500k 19,860 shares | - | +306% from low-40% from high | |
| 58Moderate | Patrick G Enright director buy | $2.3M 117,255 shares | +7% | +332% from low0% from high | |
| 50Moderate | Sr One Capital Management, LLC owner buy | $2.4M 126,315 shares | +11% | +332% from low0% from high | |
| 58Moderate | Jason Raleigh Nunn director buy | $1.2M 63,158 shares | +6% | +332% from low0% from high | |
| 62Notable | Fairmount Funds Management LLC director buy | $6.0M 316,219 shares | +17% | +224% from low-19% from high | |
| 58Moderate | Hongbo Lu director buy | $6.0M 321,983 shares | - | 0% from low0% from high | |
| 64Notable | Leon O Moulder Jr See Remarks buy | $770k 36,928 shares | - | +224% from low-19% from high | |
| 40Moderate | Ting Xiao director buy | $78k 10,000 shares | - | +20% from low-70% from high | |
| 57Moderate | Leon O Moulder Jr Chief Executive Officer buy | $718k 70,000 shares | +41% | - | |
| 39Weak | Leon O Moulder Jr Chief Executive Officer buy | $149k 10,000 shares | +6% | - |
Transactions
The last 33 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Christy J. Oliger director | AGrant or award Stock Option (Right to Buy)derivative | +37,000 | $0.00 | $0 | 37,000 | 40 d ago |
| Feb 12, 2026 | Patricia L Allen director | POpen-market purchase Common Stock | +5,000 | $23.77 | $119k | 5,000 | Feb 13, 2026 |
| Feb 12, 2026 | Patricia L Allen director | POpen-market purchase Common Stock | +5,700 | $24.34 | $139k | 10,700 | Feb 13, 2026 |
| Feb 12, 2026 | Patricia L Allen director | POpen-market purchase Common Stock | +5,000 | $26.50 | $133k | 15,700 | Feb 13, 2026 |
| Feb 13, 2026 | Patricia L Allen director | POpen-market purchase Common Stock | +4,160 | $26.36 | $110k | 19,860 | Feb 13, 2026 |
| Oct 9, 2025 | Patrick G Enright director | POpen-market purchase Common Stockindirect: See Footnote | +105,265 | $19.00 | $2.0M | 1,832,669 | Oct 14, 2025 |
| Oct 9, 2025 | Sr One Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Note 2 | +63,158 | $19.00 | $1.2M | 1,173,395 | Oct 14, 2025 |
| Oct 9, 2025 | Jason Raleigh Nunn director | POpen-market purchase Common Stockindirect: See Note 2 | +63,158 | $19.00 | $1.2M | 1,173,395 | Oct 14, 2025 |
| Oct 9, 2025 | Patrick G Enright director | POpen-market purchase Common Stock | +11,990 | $20.85 | $250k | 11,990 | Oct 14, 2025 |
| Oct 9, 2025 | Sr One Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Note 3 | +63,157 | $19.00 | $1.2M | 1,917,895 | Oct 14, 2025 |
| Sep 13, 2024 | Hongbo Lu director | POpen-market purchase Common Stockindirect: See footnote | +58,823 | $17.00 | $1000k | 58,823 | Oct 9, 2025 |
| Oct 7, 2025 | Leon O Moulder Jr See Remarks | POpen-market purchase Common Stockindirect: See Footnote | +36,928 | $20.85 | $770k | 36,928 | Oct 9, 2025 |
| Oct 7, 2025 | Fairmount Funds Management LLC director | POpen-market purchase Common Stockindirect: By Fairmount Healthcare Fund II L.P. | +316,219 | $19.00 | $6.0M | 2,209,025 | Oct 9, 2025 |
| Oct 7, 2025 | Hongbo Lu director | POpen-market purchase Common Stockindirect: See footnote | +263,160 | $19.00 | $5.0M | 321,983 | Oct 9, 2025 |
| Jun 10, 2025 | John J Orloff director | AGrant or award Stock Option (Right to Buy)derivative | +18,500 | $0.00 | $0 | 18,500 | Jun 12, 2025 |
| Jun 10, 2025 | Orlando Oliveira See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jun 12, 2025 |
| Jun 10, 2025 | Jason Raleigh Nunn director | AGrant or award Stock Option (Right to Buy)derivative | +18,500 | $0.00 | $0 | 18,500 | Jun 12, 2025 |
| Jun 10, 2025 | Leon O Moulder Jr See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +400,000 | $0.00 | $0 | 400,000 | Jun 12, 2025 |
| Jun 10, 2025 | Hongbo Lu director | AGrant or award Stock Option (Right to Buy)derivative | +18,500 | $0.00 | $0 | 18,500 | Jun 12, 2025 |
| Jun 10, 2025 | Jennifer A. Fox See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Jun 12, 2025 |
| Jun 10, 2025 | Joseph L Farmer See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Jun 12, 2025 |
| Jun 10, 2025 | Fairmount Funds Management LLC director | AGrant or award Stock Option (Right to Buy)derivativeindirect: By Tomas Kiselak | +18,500 | $0.00 | $0 | 18,500 | Jun 12, 2025 |
| Jun 10, 2025 | Patrick G Enright director | AGrant or award Stock Option (Right to Buy)derivative | +18,500 | $0.00 | $0 | 18,500 | Jun 12, 2025 |
| Jun 10, 2025 | James P Boylan director | AGrant or award Stock Option (Right to Buy)derivative | +18,500 | $0.00 | $0 | 18,500 | Jun 12, 2025 |
| Jun 10, 2025 | Patricia L Allen director | AGrant or award Stock Option (Right to Buy)derivative | +18,500 | $0.00 | $0 | 18,500 | Jun 12, 2025 |
| Feb 7, 2025 | Ting Xiao director | POpen-market purchase Common Stock | +10,000 | $7.76 | $78k | 10,000 | Apr 28, 2025 |
| Apr 15, 2025 | Lisa von Moltke See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +400,000 | $0.00 | $0 | 400,000 | Apr 17, 2025 |
| Dec 16, 2024 | Jennifer A. Fox See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +8,125 | $0.00 | $0 | 8,125 | Dec 18, 2024 |
| Dec 16, 2024 | Orlando Oliveira Chief Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +7,775 | $0.00 | $0 | 7,775 | Dec 18, 2024 |
| Dec 3, 2024 | Leon O Moulder Jr Chief Executive Officer | POpen-market purchase Common Stock | +25,000 | $10.76 | $269k | 196,155 | Dec 4, 2024 |
| Dec 4, 2024 | Leon O Moulder Jr Chief Executive Officer | POpen-market purchase Common Stock | +45,000 | $9.98 | $449k | 241,155 | Dec 4, 2024 |
| Nov 18, 2024 | Leon O Moulder Jr Chief Executive Officer | POpen-market purchase Common Stock | +7,500 | $15.00 | $113k | 168,655 | Nov 20, 2024 |
| Nov 19, 2024 | Leon O Moulder Jr Chief Executive Officer | POpen-market purchase Common Stock | +2,500 | $14.57 | $36k | 171,155 | Nov 20, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Patricia L Allendirector
- James P Boylandirector
- Patrick G Enrightdirector, owner
- Fairmount Funds Management LLCdirector, owner
- Joseph L FarmerSee Remarks
- Jennifer A. FoxSee Remarks
- Hongbo Ludirector
- Leon O Moulder JrSee Remarks
- Jason Raleigh Nunndirector
- John J Orloffdirector
- Christy J. Oligerdirector
- Orlando OliveiraSee Remarks
- Sr One Capital Management, LLCowner
- Ting Xiaodirector
- Lisa von MoltkeSee Remarks
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.